November 6, 2024
Dr Andrew Brockway at AusBiotech 2024
Dr Andrew Brockway's panel, 'Clinical Trials in Australia: Performance, Competitive Advantages, Challenges and Evolving Policy' at AusBiotech 2024
→ Register Your Interest
English
Delving further into the Doherty Clinical Trials experience and the purposes of human challenge trials, the article is another feature highlighting the company’s launch.
Doherty Clinical Trials CEO, Dr. Andrew Brockway was interviewed by The Guardian last week ahead of the launch of the not-for-profit registered charity, which was held on March 25th 2024.
Explaining the importance of human challenge trials and their purpose, the article offers an insight into the participant experience whilst underscoring the valuable insights that human challenge trials can bring. Pictured above is Brockway in the participant lounge at the Doherty Clinical Trials current facility in East Melbourne, before it moves to the AIID in the future.
You can read the full article here.
Image taken from The Guardian, captured by Ellen Smith.
Dr Andrew Brockway's panel, 'Clinical Trials in Australia: Performance, Competitive Advantages, Challenges and Evolving Policy' at AusBiotech 2024
Senior Lab Manager, Vanessa Mollard represented Doherty Clinical Trials at the forum in Canberra
Highlighting the vital work of Doherty Clinical Trials and sharing why participants find it so rewarding.
Doherty Clinical Trials launches the #mRNA Platform Incubator Network in collaboration with Moderna and other leading minds in bio-medical research
Delving further into the Doherty Clinical Trials experience and the purposes of human challenge trials, the article is another feature highlighting the company’s launch.
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}